Neurology

Back to articles

Lipophilic statins associated with decreased risk for Parkinson disease

August 2, 2013
  • Advising on this article:
  • Jack J. Chen

KEY POINT

In patients taking statins for cholesterol-lowering therapy, continuation of a lipophilic statin was associated with a lower incidence of new-onset Parkinson disease (PD) as compared to statin discontinuation, especially in female and older adult subgroups.

SOURCES

Lee YC et al. Discontinuation of statin therapy associates with Parkinson disease. Neurology. 2013;81:410–6. 

Tan EK et al. Holding on to statins in Parkinson disease [editorial]. Neurology. 2013;81:406–7.

Recent Articles

2215 Constitution Avenue NW, Washington, DC 20037 Telephone 202-628-4410 Fax 202-783-2351

© 2013 American Pharmacists Association All Rights Reserved.

About the American
Pharmacists Association

The American Pharmacists Association (APhA) is the organization whose members are recognized in society as essential in all patient care settings for optimal medication use that improves health, wellness and quality of life. Through information, education and advocacy, APhA empowers its members to improve medication use and advance patient care.

More info

About APhA DrugInfoLine

APhA DrugInfoLine (ISSN 2162-3015) is a weekly publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not neccessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that the information contained in APhA DrugInfoLine is accurate and current; however, they shall have no ability to any person or entity with regard to claims, losses, or damage caused or alleged to be caused, directly or indirectly by use of any information contained in the publication. All decisions about drug therapy must be based on independent judgement of the clinician.